Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit

费城艾滋病毒治疗和预防临床试验单位

• 批准号: 8784179
• 负责人: Ian Frank
• 金额: $ 131.57万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2020-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8784179
• 关键词: AIDS clinical trial group; AIDS prevention; Adherence; Adolescent; Adult; Advertising; Affect; Ancillary Study; Behavioral Research; Biology; Bone Diseases; Cardiovascular Diseases; Caring; Child; Childhood; Clinical Trials; Clinical Trials Unit; Communities; Community Health Education; Conduct Clinical Trials; Consequences of HIV; Data; Drug Evaluation; Epidemic; Evaluation; Faculty; Functional disorder; Future; Goals; HIV; HIV Infections; HIV Vaccine Trials Network; HIV therapy; HIV vaccine; Hepatitis B; Hepatitis C virus; Heterosexuals; Host resistance; Human Papillomavirus; Human immunodeficiency virus test; IMPAACT; Immune; Infection Control; Kidney Diseases; Leadership; Link; Malignant Neoplasms; Medical; Medicine; Mentors; Neurocognitive; New Agents; Pathogenesis; Pediatric Hospitals; Pennsylvania; Philadelphia; Population; Pregnant Women; Prevention; Prevention strategy; Prevention trial; Prophylactic treatment; Protocols documentation; Recovery; Recruitment Activity; Research; Research Infrastructure; Research Personnel; Resistance; Science; Site; Specimen; Structure; Testing; Therapeutic; Therapeutic Trials; Training; Tuberculosis; Universities; Vaccines; Vertical Disease Transmission; Virus; Work; antiretroviral therapy; clinical research site; college; cost efficient; gene therapy; immune activation; immune function; improved; innovation; intravenous drug user; medical schools; men who have sex with men; microbicide; next generation; novel; outreach; prevent; prevention clinical trial; protocol development; purge; rectal microbicide; senescence; symposium; targeted treatment; transgender; treatment strategy; vaginal microbicide; working group

DESCRIPTION (provided by applicant): The Philadelphia HIV Therapeutic and Prevention Clinical Trials Unit (Philadelphia HIV CTU-PHCTU) will provide the administrative infrastructure and scientific leadership to advance the science of HIV treatment and prevention within the five proposed HIV Research Networks, Adult Therapeutics, Therapeutics in Pediatric and Maternal Populations, Integrated Prevention, Vaccines, and Microbicides through four specific research aims: Specific Aim 1. Participate in the creation and implementation of the scientific agenda of the HIV Research Networks through committee and protocol team membership and through initiation of new Network science. Specific Aim 2. Participate in the implementation of the scientific agenda of the HIV Research Networks through the cost efficient conduct of clinical trials. Specific Aim 3. Train and mentor the next generation of HIV investigators. By engaging fellows and junior faculty in protocol development, educational conferences and clinical trials, the PHCTU will actively recruit and train the next generation of HIV investigators. Specific Aim 4. Educate the Philadelphia medical, scientific and HIV-affected communities about advances in HIV therapy and prevention. The Philadelphia HIV CTU will help to coordinate and advertise the HIV-related medical and scientific forums that currently exist, and will continue to seek input from the HIV-affected community through its Community Advisory Board and through educational outreach to HIV affected groups. The Philadelphia HIV CTU will feature an integrated, efficient clinical trials structure with four clinical research sites, three on the University of Pennsylvania (University of Pennsylvania Perelman School of Medicine-PSOM and The Children's Hospital of Philadelphia- CHOP) medical campus and one on the Drexel University medical campus, including two sites that will focus on adult HIV therapeutic trials, one that will focus on adult prevention trials, and one that will focus on trials involving pediatric ad adolescent populations. RELEVANCE: Despite numerous advances in the understanding of HIV pathogenesis, the realization of effective antiretroviral therapy (ART), and the widening scope of HIV prevention strategies, many challenges remain in the domains of HIV treatment and prevention that will need to be studied in adult, adolescent, and pediatric populations.

描述（申请人提供）：费城HIV治疗和预防临床试验部门（费城艾滋病毒CTU-PHCTU）将提供行政基础设施和科学领导，通过四个具体的研究目标，在五个拟议的艾滋病毒研究网络，成人治疗，儿科和孕产妇人群治疗，综合预防，疫苗和杀微生物剂内推进艾滋病毒治疗和预防科学：具体目标1.通过委员会和议定书小组成员以及通过启动新的网络科学，参与艾滋病毒研究网络科学议程的制定和实施。具体目标2。通过开展具有成本效益的临床试验，参与实施艾滋病毒研究网络的科学议程。具体目标3。培训和指导下一代艾滋病毒调查人员。通过让研究员和初级教师参与方案制定、教育会议和临床试验，PHCTU将积极招募和培训下一代艾滋病毒研究人员。具体目标4。教育费城医疗，科学和艾滋病毒影响的社区在艾滋病毒治疗和预防的进展。费城艾滋病毒工作队将帮助协调和宣传现有的与艾滋病毒有关的医学和科学论坛，并将继续通过其社区咨询委员会和通过对艾滋病毒感染群体的教育宣传，寻求受艾滋病毒感染社区的投入。费城艾滋病毒CTU将具有一个综合的，有效的临床试验结构，有四个临床研究中心，三个在宾夕法尼亚大学（宾夕法尼亚大学佩雷尔曼医学院-PSOM和费城儿童医院- CHOP）医学校园，一个在德雷克塞尔大学医学校园，包括两个将专注于成人艾滋病毒治疗试验的网站，一个在费城儿童医院-CHOP。 其中一个将侧重于成人预防试验，另一个将侧重于涉及儿童和青少年人群的试验。 相关性：尽管在艾滋病毒发病机制的理解，实现有效的抗逆转录病毒治疗（ART），和艾滋病毒预防策略的范围不断扩大的许多进展，许多挑战仍然存在于艾滋病毒的治疗和预防领域，将需要在成人，青少年和儿科人群中进行研究。